BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32900676)

  • 1. Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival.
    Mastroianni R; Brassetti A; Krajewski W; Zdrojowy R; Salhi YA; Anceschi U; Bove AM; Carbone A; De Nunzio C; Fuschi A; Ferriero M; Nacchia A; Pastore AL; Tema G; Tuderti G; Gallucci M; Simone G
    Eur Urol Focus; 2021 Nov; 7(6):1324-1331. PubMed ID: 32900676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes.
    Hensley PJ; Bree KK; Brooks N; Matulay J; Li R; Nogueras-Gonzalez GM; Nagaraju S; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2022 Jun; 5(3):347-356. PubMed ID: 33935020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
    Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
    Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial.
    Teoh JY; Chan ES; Yip SY; Tam HM; Chiu PK; Yee CH; Wong HM; Chan CK; Hou SS; Ng CF
    Ann Surg Oncol; 2017 May; 24(5):1428-1434. PubMed ID: 27882470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?
    Süer E; Özcan C; Baltacı S; Gülpınar Ö; Burgu B; Haliloğlu A; Bedük Y
    Urol Int; 2013; 91(2):182-6. PubMed ID: 23751593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?
    Capogrosso P; Capitanio U; Ventimiglia E; Boeri L; Briganti A; Colombo R; Montorsi F; Salonia A
    J Endourol; 2016 Apr; 30(4):400-5. PubMed ID: 26597334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
    Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H
    Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry.
    Muilwijk T; Akand M; Raskin Y; Jorissen C; Vander Eeckt K; Van Bruwaene S; Van Cleynenbreugel B; Joniau S; Van Der Aa F
    Eur Urol Oncol; 2023 Aug; 6(4):422-430. PubMed ID: 36543720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of detrusor muscle in bladder tumor specimens--predictors and effect on outcome as a measure of resection quality.
    Shoshany O; Mano R; Margel D; Baniel J; Yossepowitch O
    Urol Oncol; 2014 Jan; 32(1):40.e17-22. PubMed ID: 23911682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
    J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
    [No Abstract]   [Full Text] [Related]  

  • 16. Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.
    Suh J; Jung JH; Kwak C; Kim HH; Ku JH
    Investig Clin Urol; 2021 Jul; 62(4):408-415. PubMed ID: 34190435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.